Immatics N.V. (IMTX) Stock

Immatics N.V. (IMTX) is a Healthcare stock trading at $9.77 (as of 2026-06-18), with a market capitalization of $1.34B and a trailing P/E of -6.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Immatics N.V. is a clinical-stage biopharmaceutical company developing T cell receptor (TCR)–based immunotherapies for cancer. Its pipeline includes adoptive cell therapy and antibody-like TCR bispecific candidates, such as ACTengine programs (e.g., IMA201, IMA202, IMA203) and preclinical bispecifics (IMA401, IMA402).

Valuation — source: SEC EDGAR (first-party)
Price$9.77
Market Cap$1.34B
P/E Ratio-6.1
Price / Book2.71
DCF Value (model)$-19.85
DCF Upside vs Price-303.3%
Profitability & Growth — source: SEC EDGAR
Return on Equity-40.6%
Current Ratio11.72
Valuation vs Sector & Industry
Stock P/E-6.1
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-129.0%
vs Industry-135.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderT. Rowe Price Investment Management, Inc. ($213.06M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOHarpreet Singh
Employees554
CountryDE
IPO Date2018-12-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Oruka Therapeutics, Inc. (ORKA)
  • Relay Therapeutics, Inc. (RLAY)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Rapport Therapeutics, Inc. Common Stock (RAPP)
  • Ardelyx, Inc. (ARDX)
  • MBX Biosciences, Inc. Common Stock (MBX)
  • Tyra Biosciences, Inc. (TYRA)
  • AnaptysBio, Inc. (ANAB)
IMTX earnings history · IMTX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.